From import dependency to industrial strategy
For decades, Africa has consumed medicines it did not manufacture. Across much of the continent, between 70 and 90 percent of finished pharmaceutical products are imported. This dependence exposes African health systems to currency volatility, global supply chain disruptions, geopolitical shocks, and pricing instability.
The COVID-19 pandemic merely revealed what was already structurally fragile. But within that fragility lies opportunity. Local pharmaceutical manufacturing in Africa is no longer a patriotic aspiration. It is an industrial, economic, and public health imperative — and it presents concrete, investable opportunities for disciplined capital. The conversation must now move from advocacy to execution.
Manufacturing as health security infrastructure
Medicines are not ordinary consumer goods. They are strategic assets. When a continent of over 1.3 billion people depends primarily on imports for essential medicines, antibiotics, antimalarials, antihypertensives, oncology products, and vaccines, it carries systemic risk.
Local manufacturing is not simply about profit margins. It is about health sovereignty. Investors who understand pharmaceutical manufacturing as health infrastructure — not just a commercial play — will position themselves at the centre of Africa’s next industrial wave.
Opportunity one: Expansion of finished dosage manufacturing
The most immediate opportunity lies in scaling finished dosage form (FDF) production. Many African manufacturers already produce tablets, capsules, syrups, and intravenous fluids. The opportunity now is expansion and upgrading, particularly toward the following:
• WHO prequalification standards
• Stringent regulatory authority compliance
• Large-scale generics production
• Regional export readiness under AfCFTA
Demand is not speculative. It exists. Africa’s population is growing, urbanising, and ageing. The epidemiological transition toward chronic diseases ensures sustained pharmaceutical demand. Investment in modern production lines, automation, quality assurance systems, and regulatory compliance upgrades represents one of the most bankable entry points. This is not a startup risk. It is a scale-up opportunity.
“Africa’s population is growing, urbanising, and ageing. The epidemiological transition toward chronic diseases ensures sustained pharmaceutical demand.”
Opportunity Two: Active Pharmaceutical Ingredient (API) production
Perhaps the most strategic opportunity lies upstream – in Active Pharmaceutical Ingredient (API) manufacturing. Africa currently imports the vast majority of its APIs from Asia. This dependency exposes manufacturers to exchange rate shocks and global supply bottlenecks.
API manufacturing requires higher capital intensity, technical sophistication, and regulatory discipline. But it also offers higher strategic value and more substantial long-term margins. Targeted investment in:
• High-demand essential APIs
• Regional API industrial clusters
• Chemical synthesis capabilities
• Public-private API parks
could significantly reduce import exposure and enhance competitiveness.
Africa does not need to produce every API immediately. It needs to prioritise those linked to high-volume essential medicines strategically. Industrial strategy, not sentiment, must guide capital allocation.
Opportunity Three: Biologics and vaccine fill-and-finish
The vaccine inequity exposed during the pandemic created renewed urgency around biologics and vaccine manufacturing. Full-scale vaccine development is capital-intensive and technically complex. However, fill-and-finish facilities — where bulk vaccines are formulated and packaged locally — represent a more immediate and practical entry point.
Investments in:
• Cold chain logistics
• Sterile manufacturing facilities
• Biopharmaceutical partnerships
• Technology transfer agreements
position African manufacturers to participate meaningfully in the global biologics value chain. The continent’s long-term health resilience depends on these capabilities.
Opportunity Four: Contract manufacturing and regional hubs
Africa’s fragmented markets have historically limited economies of scale. The African Continental Free Trade Area (AfCFTA) changes that equation. Contract manufacturing organisations (CMOs) can serve multiple countries from strategically located production hubs. Regional pharmaceutical hubs — in western, eastern, southern, and northern Africa — can drive scale, efficiency, and export growth. Investors should consider:
• Multi-country distribution platforms
• Regional warehousing infrastructure
• Cross-border regulatory harmonisation support
• Strategic alliances with local distributors
Pharmaceutical manufacturing becomes more bankable when tied to regional rather than single-country demand.
Opportunity Five: Medical packaging and inputs
Often overlooked are ancillary sectors such as pharmaceutical-grade packaging, excipients, and raw material processing. Local production of:
• Blister packs
• Glass vials
• IV bags
• Pharmaceutical cartons
• Basic excipients
reduces input costs and strengthens the supply chain ecosystem. Backward integration enhances resilience and profitability. These segments often require lower entry capital than full-scale API plants, yet deliver strong industrial multipliers.
Opportunity Six: Digital traceability and quality systems
Counterfeit medicines remain a significant challenge across parts of Africa. Investment in digital traceability systems, serialisation technology, and supply chain monitoring platforms strengthens regulatory confidence and consumer trust.
Pharmaceutical manufacturing today is not merely about production capacity. It is about quality assurance, pharmacovigilance, and data transparency. Technology integration within manufacturing operations represents a high-impact, lower-visibility opportunity.
Policy alignment and regulatory reform
Capital flows where policy clarity exists. Encouragingly, several African governments are
• Offering tax incentives for local manufacturing
• Strengthening medicine regulatory authorities
• Promoting pooled procurement mechanisms
• Prioritising local content in public tenders
Investors must engage proactively with policy environments, structuring investments alongside regulatory frameworks rather than in opposition to them. Public-private partnerships will be essential.
Risk considerations
Pharmaceutical manufacturing is capital-intensive and highly regulated. Key risks include:
• Currency volatility
• Energy reliability
• Infrastructure gaps
• Regulatory inconsistency
• Access to affordable financing
However, these risks are not unique to Africa. They can be managed through structured financing models, blended capital, development finance partnerships, and regional market integration. The opportunity lies in disciplined execution, not speculative enthusiasm.
A continental industrial turning point
Africa’s pharmaceutical import bill runs into billions of dollars annually. Redirecting even a fraction of that expenditure into structured local production generates:
• Jobs
• Technical capacity
• Industrial learning
• Reduced foreign exchange exposure
• Enhanced health security
Local pharmaceutical manufacturing is not merely a sectoral opportunity. It is an industrialisation lever. It intersects healthcare, trade, industrial policy, and economic resilience.
Conclusion: From advocacy to investment
For years, local pharmaceutical production has been framed as a moral argument. It is now a financial one.
The demand exists.
The market scale exists.
The policy momentum is strengthening.
The continental trade architecture is evolving.
What is required is patient, strategic capital — capital that understands compliance, values quality, and is prepared for medium- to long-term returns. Africa does not need rhetorical support for pharmaceutical manufacturing. It requires structured investment. The opportunity is concrete. The demand is guaranteed.
The time for disciplined participation is now.
Prof Lere Baale: CEO – Business School Netherlands International – Nigeria
